SynthesisFrontiers in genetics2025
The relationship of miR-155 host gene polymorphism in the susceptibility of cancer: a systematic review and meta-analysis.
Synthesis in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Analysis of miR-155 and MIR155HG Mutations in Conjunction with TLR4 Variants in Inflammatory Joint Disease.Current issues in molecular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: miR-155 is overexpressed in many cancers, highlighting its potential as a biomarker for cancer diagnosis, treatment, and therapeutic evaluation. miR-155 is processed from the miR-155 host gene ( Material/Methods: A systematic literature search identified 15 case-control studies on three single nucleotide polymorphisms (SNPs): rs767649 (T > A), rs928883 (G > A), and rs1893650 (T > C). Meta-analysis was performed using RevMan 5.4, with odds ratios (ORs) and 95% confidence intervals (CIs) as effect measures. Results: No significant association was observed for rs767649 and rs928883 in overall cancer analysis. However, subgroup analysis revealed rs767649 increased susceptibility to respiratory, digestive, and reproductive cancers, while reducing cancer risk after excluding reproductive cancers. rs928883 showed a protective effect for digestive cancers. rs1893650 was not significantly associated with cancer risk. Conclusion:
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.